戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  inhibitors [AGIs], and insulin adjusted for glycosylated hemoglobin).
2 001) between serum protein argpyrimidine and glycosylated hemoglobin.
3  values, as well as significant decreases in glycosylated hemoglobin.
4 tis is associated with a slight elevation in glycosylated hemoglobin.
5 cerides, SBP, DBP, BMI, waist/hip ratio, and glycosylated hemoglobin.
6 esterol, total to HDL cholesterol ratio, and glycosylated hemoglobin].
7 lic blood pressure (-9.37 mm Hg; p < 0.001), glycosylated hemoglobin (-0.92%; p < 0.001), and smoking
8 table plaque and healed infarct had elevated glycosylated hemoglobin (10.2 +/- 5.0% versus 6.4 +/- 0.
9 n, mean diabetes duration 29 years, and mean glycosylated hemoglobin 7.9%).
10 f fasting serum glucose, insulin, C-peptide, glycosylated hemoglobin A (HbA1c), and Homeostasis Model
11                            The percentage of glycosylated hemoglobin A1c (%GHbA1c) in human whole blo
12 with fluorinated compounds to detect tHb and glycosylated hemoglobin A1c (GHbA1c) in human whole bloo
13 ation of less than 7.8 mmol/L (140 mg/dL) or glycosylated hemoglobin A1c (HbA1c) below 7% is unknown.
14                           Research targeting glycosylated hemoglobin A1c (HbA1c) to <6.5% to prevent
15                           Elevated levels of glycosylated hemoglobin A1c (OR, 1.47; 95% CI, 1.26-1.71
16  plasma glucose by 0.69 mmol/L [1.32; 0.07], glycosylated hemoglobin A1C by 0.37% [0.54; 0.20], body
17  gender, body mass index, diabetes duration, glycosylated hemoglobin A1c, and fasting C-peptide.
18 tegerin, osteocalcin, osteopontin, and serum glycosylated hemoglobin A1c, insulin, and glucose were a
19 adjusting for duration of diabetes mellitus, glycosylated hemoglobin A1c, statin use, and end-stage r
20 assessment-estimated insulin resistance, and glycosylated hemoglobin A1c.
21 herapy during the DCCT, smoking, and greater glycosylated hemoglobin and AER at DCCT closeout but not
22 tively and significantly related to maternal glycosylated hemoglobin and plasma glucose.
23 yperglycemic at 26 weeks of age had elevated glycosylated hemoglobin and sciatic nerve sorbitol level
24 six subjects with normal fasting glucose and glycosylated hemoglobin and seven overtly diabetic subje
25  and duration of diabetes, level of control (glycosylated hemoglobin), and demographic data were reco
26 f diabetes, treatment group, smoking status, glycosylated hemoglobin, and AER.
27 justment for age, sex, duration of diabetes, glycosylated hemoglobin, and blood pressure.
28                        Weights, blood sugar, glycosylated hemoglobin, and detailed ERGs were recorded
29               Serum lipids and lipoproteins, glycosylated hemoglobin, and the urinary albumin excreti
30 s in a 24-site US AMI registry (2005-08) had glycosylated hemoglobin assessed at a core laboratory, w
31 terol, high-density lipoprotein cholesterol, glycosylated hemoglobin, cigarette smoking) in addition
32     Total cholesterol (TC), HDL cholesterol, glycosylated hemoglobin, cigarette smoking, and hyperten
33                   Fasting plasma glucose and glycosylated hemoglobin concentrations returned to norma
34                                        Blood-glycosylated hemoglobin concentrations were not signific
35 ithout affecting body weight, blood glucose, glycosylated hemoglobin, creatinine, or creatinine clear
36                           The mean levels of glycosylated hemoglobin decreased by 1.0% in the 4 mg/d
37  adjusting for age, gender, body mass index, glycosylated hemoglobin, diabetes duration, systolic blo
38 r decline was higher after age 35 yr or when glycosylated hemoglobin exceeded 9% but did not vary wit
39 low-up, subjects who were in "poor" control (glycosylated hemoglobin (GHb) > or = 11%) at baseline we
40 han values in the WT mice; blood glucose and glycosylated hemoglobin (GHb) levels did not differ in t
41 nsive description of glycemic control (total glycosylated hemoglobin (GHb)) up to 4.5 years duration
42  cholesterol, multivessel CAD, diabetes with glycosylated hemoglobin &gt;7%, and persistent angina were
43 e the variables baseline body mass index and glycosylated hemoglobin have missing values.
44 on quality was significantly associated with glycosylated hemoglobin (Hb A(1c)) levels.
45 strates that hydroxychloroquine (HCQ) lowers glycosylated hemoglobin (HbA(1c) ) in diabetes patients
46 primary outcome (simultaneous control with a glycosylated hemoglobin (HbA(1c)) <7.0%, blood pressure
47 y disease; however, the relationship between glycosylated hemoglobin (HbA(1c)) as a marker of chronic
48 aptoglobin (Hp) polymorphism rs#72294371 and glycosylated hemoglobin (HbA(1c)) on risk of coronary he
49 al glucose tolerance test); 2) with baseline glycosylated hemoglobin (HbA1) less than 9%; and 3) who
50 8 (16.8) U/d of insulin, and had a mean (SD) glycosylated hemoglobin (HbA1) level of 10.0% (1.9%).
51 current smokers (grade A), and patients with glycosylated hemoglobin (HbA1C) >/= 6.5% (grade B).
52 current smokers (grade A), and patients with glycosylated hemoglobin (HbA1C) >/= 6.5% (grade B).
53 ncluded low-density lipoprotein </= 70mg/dl, glycosylated hemoglobin (HbA1c) </= 6.5%, and systolic b
54 4, OR10-14 years = 2.07, OR15+years = 3.99), glycosylated hemoglobin (HbA1c) (OR6.5-6.9% = 1.33, OR7-
55 designed to examine the relationship between glycosylated hemoglobin (HbA1C) and adverse outcomes in
56 abetes control was assessed by percentage of glycosylated hemoglobin (HbA1c) and divided into three c
57  the effects of ranolazine versus placebo on glycosylated hemoglobin (HbA1c) at 6- and 12-month follo
58                   The duration of DM and the glycosylated hemoglobin (HbA1c) levels of the patients i
59 diators did not correlate with age, race, or glycosylated hemoglobin (HbA1C) levels.
60  risk of those outcomes at both high and low glycosylated hemoglobin (HbA1c) levels.
61 nother agent in the 120 days after the index glycosylated hemoglobin (HbA1C) measurement.
62  Mental State Examination of 28.6 +/- 1.5, a glycosylated hemoglobin (HbA1C) of 5.88 +/- 0.74%, and a
63                                    Recently, glycosylated hemoglobin (HbA1c) of 6.5% or higher (>/= 4
64                                              Glycosylated hemoglobin (HbA1c) was assessed using a cha
65 the levels of the fasting plasma glucose and glycosylated hemoglobin (HbA1c) were compared in both gr
66                             Body mass index, glycosylated hemoglobin (HbA1c), and DPN [quantified by
67 nder-the-curve glucose after glucose load or glycosylated hemoglobin (HbA1c), and measures of insulin
68  index (BMI), blood pressure, serum glucose, glycosylated hemoglobin (HbA1c), blood urea nitrogen, se
69                                    Admission glycosylated hemoglobin (HbA1c), glucose levels, and com
70 rement of random blood glucose levels, serum glycosylated hemoglobin (HbA1c), serum porcine C peptide
71 short-term reduction in the concentration of glycosylated hemoglobin (HbA1c).
72  association between H. pylori and levels of glycosylated hemoglobin (HbA1c).
73 h type 2 diabetes and poor glycemic control (glycosylated hemoglobin [HbA1c] levels > or =8.0%) and p
74 DM (mean duration, 7.7 [SD, 7.2] years; mean glycosylated hemoglobin [HbA1c] value, 7.4% [SD, 1.0%]),
75  hypertension (>130/80 mm Hg) and type 2 DM (glycosylated hemoglobin [HbA1c], 6.5%-8.5%) and were rec
76 factor changes (fasting blood glucose [FBG], glycosylated hemoglobin [HbA1c], systolic or diastolic b
77 s to these bacteria, and blood sugar levels (glycosylated hemoglobin, HbAlc) were studied before and
78 estimates for glycosylated hemoglobin (total glycosylated hemoglobin, hemoglobin A1, or hemoglobin A1
79 r increased extent of macular edema), higher glycosylated hemoglobin, history of diabetic neuropathy,
80 sting glucose is 91.6+/-13.8 mg/dl, and mean glycosylated hemoglobin is 5.1+/-0.7% (normal range: 4.3
81                                              Glycosylated hemoglobin is an indicator of long-term gly
82 he purpose of this study was to determine if glycosylated hemoglobin is elevated in patients with per
83 luded age, gender, BP, body mass index, GFR, glycosylated hemoglobin, LDL cholesterol, HDL cholestero
84 inuria of short duration, salutary levels of glycosylated hemoglobin (less than 8 percent), low systo
85 represented a 1-percentage point increase in glycosylated hemoglobin level (95% CI, 1.10 to 1.26) in
86 ssure (diabetic and nondiabetic patients) or glycosylated hemoglobin level (diabetic patients only).
87 hospitalization were longitudinally measured glycosylated hemoglobin level (rate ratio = 1.5 per 2% i
88 among patients with diabetes, only 28% had a glycosylated hemoglobin level measured.
89 of metformin-rosiglitazone, 28.1% achieved a glycosylated hemoglobin level of 7% or less [corrected].
90 ose level of 12.0 mmol/L (216 mg/dL), a mean glycosylated hemoglobin level of 8.8%, and a mean body m
91 during the open treatment phase (mean +/- SD glycosylated hemoglobin level reduction, -0.4% +/- 1.4%;
92 diabetes, chronic hyperglycemia (assessed by glycosylated hemoglobin level) is related to the develop
93 waist-to-hip ratio, physical activity index, glycosylated hemoglobin level, and other factors.
94 italization in the preceding 6 months, lower glycosylated hemoglobin level, and questionnaire respons
95 controlling for age, sex, cigarette smoking, glycosylated hemoglobin level, insulin use, plasma C-pep
96 gnificantly correlated with blood glucose or glycosylated hemoglobin level.
97 sting glucose: 9.9 (2.5) mmol/dL, and HbA1c (glycosylated hemoglobin) level: 8.9% (1.2%).
98                                              Glycosylated hemoglobin levels and insulin doses were al
99 style, there was a significant difference in glycosylated hemoglobin levels between those who rated t
100                                              Glycosylated hemoglobin levels decreased during the open
101                              Deaths and mean glycosylated hemoglobin levels did not differ between th
102 reatment are associated with improvements in glycosylated hemoglobin levels for at least 1 year.
103 ble to discontinue insulin therapy and their glycosylated hemoglobin levels improved.
104                                              Glycosylated hemoglobin levels remained significantly lo
105                                         Mean glycosylated hemoglobin levels were 5.2+/-0.9% (off ster
106 our postdextrose glucose concentrations, and glycosylated hemoglobin levels were available from 11 27
107 than for white girls in every age group, and glycosylated hemoglobin levels were highest for black an
108 reports from 1966 through June 1994 in which glycosylated hemoglobin levels were measured concurrentl
109                               Post-treatment glycosylated hemoglobin levels were not different in the
110 ferent in the two groups, but follow-up mean glycosylated hemoglobin levels were significantly better
111                                              Glycosylated hemoglobin levels, fasting plasma glucose l
112 ts, emergency department visits, death rate, glycosylated hemoglobin levels, medications, and past me
113 tory; glycemic control was measured by using glycosylated hemoglobin levels.
114 mproved glucose tolerance and a reduction in glycosylated hemoglobin levels.
115 iabetic medication were further adjusted for glycosylated hemoglobin levels.
116 ch was assessed via serial determinations of glycosylated hemoglobin levels.
117  also associated in the CVRF-free group with glycosylated hemoglobin levels.
118 ssure, high-density lipoprotein cholesterol, glycosylated hemoglobin, lipoprotein(a) and fibrinogen l
119 e <120/80 mm Hg, fasting glucose <100 mg/dl, glycosylated hemoglobin &lt;5.7%, and total cholesterol <20
120  [systolic <130 mm Hg; diastolic <80 mm Hg], glycosylated hemoglobin &lt;7%) in BARI 2D.
121 or pneumococcal vaccination to 88% for serum glycosylated hemoglobin measurement.
122 t, blood pressure, random serum glucose, and glycosylated hemoglobin measurements.
123  of diabetic retinopathy was associated with glycosylated hemoglobin (odds ratio [OR], 1.27; 95% CI,
124 sly unknown DM, defined by a core laboratory glycosylated hemoglobin of >/=6.5%.
125 nor documentation of DM in the chart (median glycosylated hemoglobin of unrecognized patients, 6.7%;
126 to the previously established role for total glycosylated hemoglobin, other factors including height,
127  plasma glucose concentration, percentage of glycosylated hemoglobin, plasma insulin concentration, a
128 rs of progression to definite DSP were total glycosylated hemoglobin (relative risk (RR) for increase
129                                              Glycosylated hemoglobin, serum glucose while fasting, se
130 and endorsed as an acceptable screen for DM, glycosylated hemoglobin testing should be considered for
131            Glucose tolerance, C-peptide, and glycosylated hemoglobin tests confirmed the restoration
132                 Moreover, by measuring total glycosylated hemoglobin (TGH) in 997 pregnant women as a
133 rovascular disease; however, the relation of glycosylated hemoglobin to macrovascular disease is less
134 MI); lipid profile; and levels of glucose or glycosylated hemoglobin, to identify those with metaboli
135         Adjusted relative risk estimates for glycosylated hemoglobin (total glycosylated hemoglobin,
136 e incidence of neuropathy was related to the glycosylated hemoglobin value and the duration of diabet
137 liter], P<0.001), respectively, and the mean glycosylated hemoglobin value decreased 1.2 percentage p
138 ent glycosylated hemoglobin value, change in glycosylated hemoglobin value during the follow-up perio
139 ary albumin excretion rate and with the mean glycosylated hemoglobin value during the mean duration (
140                 The absolute decrease in the glycosylated hemoglobin value was 1.9 percent (95 percen
141  we found that duration of diabetes, current glycosylated hemoglobin value, change in glycosylated he
142    Poorly controlled diabetes was defined as glycosylated hemoglobin values > 8%.
143                  Minimal differences in mean glycosylated hemoglobin values (HbAlc) were noticed befo
144                            The adjusted mean glycosylated hemoglobin values decreased by 0.8 and 1.4
145                                     The mean glycosylated hemoglobin values have been dramatically re
146 ations during fasting and postprandially and glycosylated hemoglobin values were measured periodicall
147 nsulin-dependent (type 2) diabetes mellitus (glycosylated hemoglobin values, 8 to 12 percent; normal,
148                                              Glycosylated hemoglobin was only measured in patients wi
149 c model assessment of insulin resistance and glycosylated hemoglobin were measured from a fasting blo
150           Samples for plasma glucose and for glycosylated hemoglobin were obtained at 24-28 weeks' ge
151                                              Glycosylated hemoglobin, which was 10.4% pretreatment, d

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top